

# Oregon Prescription Drug Monitoring Program 2020 4th Quarter Report


Percentage change evaluated relative to 4th Quarter, 2019

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



## Summary

- Web queries have decreased in comparison to 2019 Q4. This is likely due to increased adoption of query systems that are integrated within existing electronic medical record systems.
- Prescriptions for gabapentin have increased the most since 2019 Q4 (+ 1,217%) relative to other controlled substances (Table 5) , as gabapentin was only recently added as a PDMP controlled substance.
- Amphetamine prescriptions have increased (+ 12.3%) and methylphenidate prescriptions slightly decreased (- 0.9%) compared to 2020 Q4.
- Disruption to typical medical care practices caused by the COVID-19 pandemic may have influenced the numbers reported here.



† Query data drawn from Appriss AWAxRxE and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

# Oregon Prescription Drug Monitoring Program 2020 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2019

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



**Table 1. PDMP Queries Summary Statistics: October-December, 2020**

Measure	Web Portal	% Change*	Integrated
Queries †	216,308	- 33.7 %	5,895,084
Healthcare providers	58,517	- 33.5 %	4,985,318
Pharmacies	49,305	- 39.6 %	909,766
Delegates	108,420	- 30.7 %	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- The number of integrated queries continues to increase.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics, and pharmacies.

**Table 2. Special Requests: October-December, 2020**

Measure	Count
Special Requests Total	73
Patient Records	6
Healthcare Board	65
Law Enforcement	2

- 73 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

\* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxR web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2020 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2019

healthoregon.org/pdmp



Table 3. PDMP Enrollment and System Use: October-December, 2020

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
All Prescribers	18,429	15,585 / 84.6 %	4,580 / 29.4 %	10,497 / 67.4 %	11,664 / 74.8 %
Top 4K Prescribers	4,000	3,843 / 96.1 %	2,007 / 52.2 %	3,261 / 84.9 %	3,519 / 91.6 %
Top 2K Prescribers	2,000	1,936 / 96.8 %	1,142 / 59 %	1,678 / 86.7 %	1,805 / 93.2 %

- During the 4th quarter of 2020 there were 18,429 prescribers who wrote a prescription for a controlled substances in Oregon.
- By the close of the 4th quarter, 84.6 % of enrolled prescribers had queried the system; 96.1 % of the top 4,000 prescribers; 96.8 % of the top 2,000 prescribers through the web portal or an integrated system.
- The percentage of prescribers who queried the system, either through the web or integration, was higher in the 4th quarter of 2020 than the 4th quarter of 2019.

Table 4. PDMP Query by Clinical User Group: October-December, 2020

Discipline	Total User Accounts	% Change*	Web Users <sup>±†</sup>	% Change*	Integrated Users
MD/PA/DO	20,365	- 12.8 %	1,672	- 31.4 %	12,618
NP/CNS-PP	7,039	- 33.3 %	865	- 14.7 %	2,918
RPh	6,186	- 37.9 %	1,422	- 16.7 %	284
Delegates	5,621	- 38.0 %	1,814	- 23.6 %	-
DDS/DMD	5,681	- 41.5 %	343	- 30.4 %	202
ND	3,629	- 53.1 %	135	- 14.0 %	397

- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing as more systems switch to an integrated platform.
- Total user accounts may have decreased due to periodic removal of inactive accounts, which is done as a data security precaution.

\* Percentage change figures evaluated relative to the same time period during the prior year.

± Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2020 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2019

healthoregon.org/pdmp



Table 5. Top Prescriptions: October-December, 2020

Drug	# of Rx	% of all Rx	% Change*
All	1,688,730	100 %	+ 15.4 %
Hydrocodone	250,191	14.8 %	- 3.0 %
Oxycodone	233,415	13.8 %	+ 2.7 %
Gabapentin	227,480	13.5 %	+ 1,217 %
Amphetamine	156,499	9.3 %	+ 12.3 %
Lorazepam	86,017	5.1 %	+ 5.3 %
Tramadol	84,842	5.0 %	- 0.4 %
Methylphenidate	71,653	4.2 %	- 0.9 %
Zolpidem	69,845	4.1 %	- 3.0 %
Alprazolam	63,810	3.8 %	- 0.9 %
Clonazepam	62,442	3.7 %	+ 0.9 %

- Prescriptions for gabapentin increased, reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.
- Prescriptions for amphetamine increased relative to the same quarter last year.
- Oxycodone prescriptions increased, while hydrocodone decreased.

Table 6. Prescriptions for Buprenorphine and Naloxone: October-December, 2020

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	40,948	2.4 %	+ 31.0%
Buprenorphine/Naloxone	23,393	1.4 %	- 13.4 %
Naloxone	4,347	0.3 %	+ 35.2 %

- Prescriptions for buprenorphine and naloxone have increased, while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, [pdmp.research@state.or.us](mailto:pdmp.research@state.or.us)

\* Percentage change figures evaluated relative to the same time period during the prior year